Evidence map›Paper›PMID 41574967›Full record

ArticleJournal of sleep research2026

Increased p-Tau181 Levels After Overnight Wakefulness Are Associated With Neuroticism in Young Women.

Diana A Nôga, Elisa M S Meth, Abdullah Almajni, Viviana Rossi, Camilla Zetterlund, Samira F M Noory, Michaela Danek, Asma Al-Grety, André P Pacheco, Meina Wu and 5 more

Abstract read
In one paragraph

Article in Journal of sleep research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Diana A NôgaDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Elisa M S MethDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Abdullah AlmajniDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Viviana RossiDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Camilla ZetterlundDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Samira F M NooryDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Michaela DanekDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0009-0005-8366-990X
Asma Al-GretyDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Akademiska Sjukhuset, Uppsala, Sweden.ORCID https://orcid.org/0009-0006-9608-4297
André P PachecoDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Meina WuDepartment of Neurology and Sleep Medical Center, Fujian Provincial Governmental Hospital, Fuzhou, China.
Mia PhillipsonDepartment of Medical Cell Biology, the Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Kim KultimaDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Akademiska Sjukhuset, Uppsala, Sweden.
Pei XueDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Christian BenedictDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.

Funding

AD Strategic Fund and the Alzheimer's Association #ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C and #ADSF-24-1284328-CÅke Wiberg Stiftelse M24-0251Alzheimer Drug Discovery Foundation (ADDF), USA #201809-2016862Bluefield ProjectCure Alzheimer's FundEuropean Partnership on MetrologyEuropean Union Joint Programme-Neurodegenerative Disease Research JPND2021-00694European Union's Horizon Europe research 101053962European Union's Horizon Europe Research and Innovation Programme NEuroBioStand, #22HLT07Familjen Beiglers StiftelseFamiljen Rönströms StiftelseHjärnfonden FO2023-0292Marie Skłodowska-Curie grant 860197National Institute for Health and Care ResearchNovo Nordisk Fonden NNF23OC0081873Olav Thon Foundation, the Erling-Persson Family FoundationPharmaceutical Biosciences at Uppsala University, SwedenStiftelsen för Gamla TjänarinnorSwedish State Support for Clinical Research #ALFGBG-71320UK Dementia Research Institute UKDRI-1003University College London Hospitals Biomedical Research CentreVetenskapsrådet 2019-02397Vetenskapsrådet 2022-01018Vetenskapsrådet 2023-00356
6 · The paper itself

Abstract

Night shift work can impair attention and increase biomarkers linked to neurodegenerative processes. Understanding factors that influence resilience to, or vulnerability under, sleep loss is therefore essential for identifying groups at particular risk. In this within-subjects study, we examined two potential modulators of vulnerability in 54 healthy, naturally cycling women aged 21-33 years: the ovarian hormone estradiol, known for its neuroprotective properties and the personality trait neuroticism, previously associated with stress sensitivity. Participants completed one night of habitual sleep followed by one night of overnight wakefulness, mimicking a transition from an off- to an on-night shift. Women with higher morning blood estradiol levels or lower neuroticism (indexed by higher emotional stability scores) exhibited non-significant tendencies towards faster reaction times during successful psychomotor vigilance test (PVT) trials, which assess sustained attention. Notably, lower neuroticism was also associated with significantly fewer attentional lapses (reaction times ≥ 500 ms) during the PVT, whereas estradiol levels were not. However, neither trait modulated the overall decline in attentional performance observed following the night-shift condition. In contrast, higher neuroticism-but not estradiol-predicted elevated morning levels of phosphorylated tau at threonine 181 (p-Tau181), a plasma biomarker associated with Alzheimer's disease-related neurodegenerative processes, after the night shift condition. These findings highlight neuroticism as a psychological factor linked to increased neurobiological sensitivity to overnight wakefulness among women.

Indexed as

Anxiety DisordersNeuroticismtau ProteinsWakefulnessAdultAttentionBiomarkersEstradiolFemaleHumansPsychomotor PerformanceReaction TimeYoung AdultBiomarkersEstradioltau ProteinsAlzheimer's disease biomarkerestradiolneuroticismnight shift workpsychomotor vigilancewomen

Identifiers

PMID41574967
PMCPMC13357770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.